IPH 2101 Uses, Dosage, Side Effects and more

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

Trade Name IPH 2101
Generic IPH 2101
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.

How IPH 2101 works

The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share